Both coy’s are still years away from anything substantial. However, with the only main competitor being Merck & Co.’s oral tricyclic macrocycle MK-0616, this remains a huge market opportunity for NYR’s own PCSK9-inhibitor.
The space both coy’s are playing in is vast and big pharma will be watching it intently. Remember Bonnar’s plan is to pass these compounds onto other companies with superior infrastructure that can take the various drug candidates NYR have through late-stage development. Global sales of statins in 2017 were approximately US$19 billion; a massive, massive space to be playing in.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)